title: Radiofrequency Ablation for Liver Metastases after Transarterial Chemoembolization: A Systemic Analysis.
abstract: BACKGROUND
  This systemic analysis was conducted to evaluate tumor recurrence rate and one-year survival rate for patients with liver metastases received radiofrequency ablation after transarterial chemoembolization and introduce a new method of radiofrequency ablation by puncture navigation technology for single liver metastases after transarterial chemoembolization.
  
  
  METHODS
  Clinical studies evaluating tumor recurrence rate and one-year survival rate. Appling the innova trackvision software to process one liver metastases received transarterial chemoembolization and using radiofrequency ablation by puncture navigation technology to treat the liver metastases.
  
  
  RESULTS
  3 clinical studies which including 235 patients with liver metastases after transaeterial chemoembolization were considered eligible for inclusion. Systemic analysis suggested that tumor recurrence rate was 23% (54/235), one-year survival rate was 76% (178/235). The new procedure was performed successfully and the patient received a good prognosis.
  
  
  CONCLUSIONS
  This systemic analysis suggests that radiofrequency ablation is a good method for liver metastases after transarterial chemoembolization and could receive a relatively good prognosis.
authors.affiliation: Department of Interventional Radiology, Subei People's Hospital of Jiangsu Province, Clinical Hospital of Yangzhou University, Yangzhou, China E-mail : why77sina.com; huangxinen06@163.com.
authors.forename: Chuan
authors.initials: C
authors.lastname: Xu
authors.forename: Peng-Hua
authors.initials: PH
authors.lastname: Lv
authors.forename: Xin-En
authors.initials: XE
authors.lastname: Huang
authors.forename: Shu-Xiang
authors.initials: SX
authors.lastname: Wang
authors.forename: Ling
authors.initials: L
authors.lastname: Sun
authors.forename: Fu-An
authors.initials: FA
authors.lastname: Wang
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D017115:Catheter Ablation / Q000401:mortality*; D016461:Chemoembolization, Therapeutic / Q000009:adverse effects*; D002986:Clinical Trials as Topic; D006801:Humans; D008113:Liver Neoplasms / Q000150:complications* / Q000401:mortality / Q000556:secondary / Q000628:therapy; D015201:Meta-Analysis as Topic; D009364:Neoplasm Recurrence, Local / Q000209:etiology / Q000401:mortality* / Q000473:pathology / Q000628:therapy*; D009367:Neoplasm Staging; D011379:Prognosis; D015996:Survival Rate